NCT01172756View on ClinicalTrials.gov

A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Diastolic Dysfunction

PHASE2TerminatedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

July 31, 2010

Primary Completion Date

October 31, 2012

Study Completion Date

October 31, 2012

Conditions
Hypertension, PulmonaryVentricular Dysfunction, Left
Interventions
DRUG

Riociguat (BAY63-2521)

0.5 mg single oral dose

DRUG

Riociguat (BAY63-2521)

1 mg single oral dose

DRUG

Riociguat (BAY63-2521)

2 mg single oral dose

DRUG

Placebo

single oral dose

Trial Locations (7)

1090

Vienna

4010

Linz

5020

Salzburg

8020

Graz

8036

Graz

12808

Prague

50924

Cologne

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY